Functional Assessment ofTSC2 Variants Identified in Individuals with Tuberous Sclerosis Complex
- 17 August 2012
- journal article
- research article
- Published by Hindawi Limited in Human Mutation
- Vol. 34 (1) , 167-175
Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in the TSC1 or TSC2 genes. The TSC1 and TSC2 gene products, TSC1 and TSC2, form a complex that inhibits the mammalian target of rapamycin (mTOR) complex 1 (TORC1). Here, we investigate the effects of 78 TSC2 variants identified in individuals suspected of TSC, on the function of the TSC1–TSC2 complex. According to our functional assessment, 40 variants disrupted the TSC1–TSC2‐dependent inhibition of TORC1. We classified 34 of these as pathogenic, three as probably pathogenic and three as possibly pathogenic. In one case, a likely effect on splicing as well as an effect on function was noted. In 15 cases, our functional assessment did not agree with the predictions of the SIFT amino acid substitution analysis software. Our data support the notion that different, nonterminating TSC2 mutations can have distinct effects on TSC1–TSC2 function, and therefore, on TSC pathology.Keywords
This publication has 23 references indexed in Scilit:
- Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidenceEuropean Journal of Human Genetics, 2011
- Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis ComplexHuman Mutation, 2011
- A reliable cell-based assay for testing unclassified TSC2 gene variantsEuropean Journal of Human Genetics, 2008
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growthBiochemical Journal, 2008
- Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioningJournal of Cell Biology, 2006
- TSC1 Stabilizes TSC2 by Inhibiting the Interaction between TSC2 and the HERC1 Ubiquitin LigaseJournal of Biological Chemistry, 2006
- The GTPase-activating protein Rap1GAP uses a catalytic asparagineNature, 2004
- Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberinHuman Molecular Genetics, 2001
- The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitinationOncogene, 2000
- Identification and characterization of the tuberous sclerosis gene on chromosome 16Cell, 1993